Free Trial
→ Why Some AI Stocks Already Surged Over 300 Percent (From Brownstone Research) (Ad)tc pixel
NASDAQ:GHRS

GH Research Q3 2026 Earnings Date & Estimates

GH Research logo
$18.70 -0.15 (-0.79%)
Closing price 03:59 PM Eastern
Extended Trading
$18.57 -0.14 (-0.73%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GH Research is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from GH Research in Q3 2026

GH Research is expected to post earnings of -$0.3122 per share. In the same quarter a year earlier GH Research reported -$0.23 per share. GH Research last reported on August 6, 2026, posting -$0.23 per share and beating the -$0.2860 consensus estimate. GH Research has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.3122
Prior-Year EPS
-$0.23

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.23 (Beat by +$0.0560)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

GH Research Q3 2026 Earnings FAQ

GH Research (NASDAQ:GHRS) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

GH Research's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect GH Research to post earnings of -$0.3122 per share for Q3 2026.

GH Research Earnings Headlines

GH Research to Present TRD and Bipolar Trial Data at ECNP 2026
October 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/gh-research-to-present-trd-and-bipolar-trial-data-at-ecnp-2026?utm_source=marketbeat.com&utm_medium=referral
GH Research PLC (NASDAQ:GHRS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082998
I have publicly predicted six major American crashes, before each one happened.
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
October 14 at 1:00 AM  |  Weiss Ratings (Ad)
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities
September 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4948138-gh-research-buy-gh001-trd-advancement-presses-on-and-expansion-opportunities
GH Research Files Q2 2026 Results and Updates Corporate Presentation
August 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/gh-research-files-q2-2026-results-and-updates-corporate-presentation?utm_source=marketbeat.com&utm_medium=referral
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340118/0/en/gh-research-reports-second-quarter-2026-financial-results-and-provides-business-update.html
See More GH Research Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email.

About GH Research

GH Research (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company focused on developing novel treatments for psychiatric and neurological disorders. The company’s research centers on mebufotenin, also known as 5-MeO-DMT, a psychedelic compound being evaluated through proprietary formulations and delivery methods designed to produce rapid-acting therapeutic effects.

GH Research’s lead investigational program, GH001, is an inhaled formulation of mebufotenin being studied for major depressive disorder, including treatment-resistant depression. The company is also developing additional mebufotenin-based programs, including formulations intended for alternative routes of administration. These products remain investigational, and GH Research does not currently market an approved therapy.

Headquartered in Dublin, Ireland, GH Research conducts clinical development activities internationally through studies involving patients in multiple regions. The company’s programs are focused on addressing psychiatric conditions for which existing treatments may have limited effectiveness or a delayed onset of action.

View GH Research Profile
Earnings Tools